Today’s Highlights- Prohost Biotech - Exclusive Biotech Research

Category: Today’s Highlights

Kura Oncology (KURA): Battling Resistant Head & Neck Cancers

Positive Phase 2 Results for Tipifarnib in HRAS Mutant Head and Neck Cancer Four of the first six HRAS Mutant HNSCC Patients enrolled on study achieve confirmed RECIST Partial Responses and Durable Responses Greater than One Year On September...

September 12, 2017

Two Large Pharma Agreements with Halozyme in One Day. HALO Rallied

Following the announcement of two new licensing agreements for its ENHANZE ® drug-delivery technology, Halozyme Therapeutics (HALO) raised financial guidance for 2017 as follows: - Net revenue of $245 million to $260 million, an increase of $130 million from the prior range of $115...

September 14, 2017

Exelixis is Still a Favorite

EXELIXIS Being called overvalued by one analyst does not mean that Exelixis (EXEL) is, indeed, overvalued. We believe it is not and that’s why we decided to accumulate the stock on any weaknesses in EXEL. We do not intend to...

September 22, 2017

Will NewLink Genetics' IDO Inhibitor Improve the Efficacy of AstraZeneca's Checkpoint Inhibitor in Treating Pancreatic Cancer?

AstraZeneca’s (AZN) checkpoint PD-L1 inhibitor Imfinzi and NewLink Genetics’ (NLNK) IDO inhibitor indoximod will be combined and tested in Phase 2 randomized, placebo-controlled clinical trials together with the standard of care chemotherapy treatment for metastatic pancreatic cancer . AstraZeneca and...

September 28, 2017

Motif Bio Has Good News. Amicus Therapeutics Has a Series of Good News

MOTIF BIO Antibiotic Motif Bio’s (MTFB ) antibiotic drug Iclaprim met the Phase 3 Revive-2 trial’s primary endpoints of non-inferiority against the current standard of care antibiotic, vancomycin in acute bacterial skin and skin structure infections (ABSSSI). The drug demonstrated a...

October 5, 2017

Incyte and Calithera Collaboration Is Fair and Lucrative for Both Firms

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a Small Molecule Arginase Inhibitor Incyte (INCY) and Calithera Biosciences ( CALA ) announced a global...

January 30, 2017

While You Were Sleeping

A few months ago, we heard news that a Belgium firm called Celyad (CYAD) has concluded a deal worth over $300 million with Ono Pharmaceutical. The deal gives Ono the rights to Celyad’s allogeneic NKR-2 T-cell immunotherapy in Japan, Korea...

January 17, 2017

Will the FDA Approve Amgen's Drug Parsabiv Next Month?

Amgen (AMGN) The Journal of the American Medical Association ( JAMA ) published findings from three Phase 3 studies of Parsabiv (etelcalcetide) , an investigational intravenous calcimimetic agent in the U.S. The studies evaluated Amgen’s drug Parsabiv in more than...

January 11, 2017

Some More Important News that Precedes the Upcoming Prohost Letter

GILEAD (GILD) One analyst who aimed at bringing only the negatives about biotech has finally succeeded in convincing other critics and media bloggers that Gilead would not be good for investment until the firm acquires a company that can expand...

January 5, 2017

A Few News Before Posting the New Year Prohost Letter

Hi and Happy New Year 2017 In a couple of days, you will receive the NEW Year 2017 issue #404 of the Prohost Letter where we will set out our prediction regarding breakthrough achievements that we believe will change the...

January 3, 2017

Search ProhostBiotech

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis

September 19, 2024

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024